BD PharmingenTM FITC Mouse Anti-Human IFN-gamma

Description

Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophore A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop Cat. No. 554724 . The PBMC were stained with PE-Cy5 anti-CD3 Cat. No. 555334/561007 , fixed and permeabilized with BD Cytofix/Cytoperm Plus Kit with BD GolgiStop Cat. No. 554715 , then subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma antibody Cat. No. 554700/552887/561053; left panel . To demonstrate specificity of staining, binding by the FITC Mouse Anti-Human IFN-gamma antibody was blocked by preincubation of fixed/permeabilized cells with excess Purified Mouse Anti-Human IFN-gamma antibody Cat. No. 554699/550011, right panel . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls, and verified using the unlabeled B27 antibody blocking control. Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophore A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop Cat. No. 554724 . The PBMC were stained with PE-Cy5 anti-CD3 Cat. No. 555334/561007 , fixed and permeabilized with BD Cytofix/Cytoperm Plus Kit with BD GolgiStop Cat. No. 554715 , then subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma antibody Cat. No. 554700/552887/561053; left panel . To demonstrate specificity of staining, binding by the FITC Mouse Anti-Human IFN-gamma antibody was blocked by preincubation of fixed/permeabilized cells with excess Purified Mouse Anti-Human IFN-gamma antibody Cat. No. 554699/550011, right panel . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls, and verified using the unlabeled B27 antibody blocking control. Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophore A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop Cat. No. 554724 . The PBMC were stained with PE-Cy5 anti-CD3 Cat. No. 555334/561007 , fixed and permeabilized with BD Cytofix/Cytoperm Plus Kit with BD GolgiStop Cat. No. 554715 , then subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma antibody Cat. No. 554700/552887/561053; left panel . To demonstrate specificity of staining, binding by the FITC Mouse Anti-Human IFN-gamma antibody was blocked by preincubation of fixed/permeabilized cells with excess Purified Mouse Anti-Human IFN-gamma antibody Cat. No. 554699/550011, right panel . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls, and verified using the unlabeled B27 antibody blocking control. Show More Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophore A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop Cat. No. 554724 . The PBMC were stained with PE-Cy5 anti-CD3 Cat. No. 555334/561007 , fixed and permeabilized with BD Cytofix/Cytoperm Plus Kit with BD GolgiStop Cat. No. 554715 , then subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma antibody Cat. No. 554700/552887/561053; left panel . To demonstrate specificity of staining, binding by the FITC Mouse Anti-Human IFN-gamma antibody was blocked by preincubation of fixed/permeabilized cells with excess Purified Mouse Anti-Human IFN-gamma antibody Cat. No. 554699/550011, right panel . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls, and verified using the unlabeled B27 antibody blocking control. Show More Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophore A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop Cat. No. 554724 . The PBMC were stained with PE-Cy5 anti-CD3 Cat. No. 555334/561007 , fixed and permeabilized with BD Cytofix/Cytoperm Plus Kit with BD GolgiStop Cat. No. 554715 , then subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma antibody Cat. No. 554700/552887/561053; left panel . To demonstrate specificity of staining, binding by the FITC Mouse Anti-Human IFN-gamma antibody was blocked by preincubation of fixed/permeabilized cells with excess Purified Mouse Anti-Human IFN-gamma antibody Cat. No. 554699/550011, right panel . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls, and verified using the unlabeled B27 antibody blocking control. Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophore A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop Cat. No. 554724 . The PBMC were stained with PE-Cy5 anti-CD3 Cat. No. 555334/561007 , fixed and permeabilized with BD Cytofix/Cytoperm Plus Kit with BD GolgiStop Cat. No. 554715 , then subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma antibody Cat. No. 554700/552887/561053; left panel . To demonstrate specificity of staining, binding by the FITC Mouse Anti-Human IFN-gamma antibody was blocked by preincubation of fixed/permeabilized cells with excess Purified Mouse Anti-Human IFN-gamma antibody Cat. No. 554699/550011, right panel . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls, and verified using the unlabeled B27 antibody blocking control.